Patents Examined by Timothy R Rozof
  • Patent number: 10707019
    Abstract: An electro-polarizable compound has the following general formula: where Core1 is an aromatic polycyclic conjugated molecule having two-dimensional flat form and self-assembling by pi-pi stacking in a column-like supramolecule, which is tetrapirolic macro-cyclic fragment, R1 is an dopant group connected to Core1, m is number of R1 which is equal to 1, 2, 3 or 4, R2 is a substituent comprising one or more ionic groups, p is number of R2 which is equal to 0, 1, 2, 3 or 4. The fragment marked NLE containing the Core1 with at least one R1 has a nonlinear effect of polarization. Core2 is an electro-conductive oligomer self-assembling by pi-pi stacking in a column-like supramolecule, n is number of Core2 which is equal to 2, or 4, R3 is a substituent comprising one or more ionic groups, s is number of R3 which is equal to 0, 1, 2, 3 or 4. R4 is a non-polar resistive substituent, k is a number of R4 which is equal to 0, 1, 2, 3, 4, 5, 6, 7 or 8.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: July 7, 2020
    Assignee: CAPACITOR SCIENCE INCORPORATED
    Inventors: Pavel Ivan Lazarev, Paul T. Furuta, Barry K. Sharp, Yan Li
  • Patent number: 10696685
    Abstract: The invention is among others concerned with novel polyketides, their method of production, purification and use. The method can entail providing a bacterium that synthesizes the compound.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: June 30, 2020
    Assignee: Universiteit Leiden
    Inventors: Changsheng Wu, Young-Hae Choi, Gilles Philippus van Wezel
  • Patent number: 10689380
    Abstract: Disclosed herein are new crystalline forms of valbenazine ditosylate designated Form D and Form E, which are characterized using one or more analytical methods, such as X-ray Powder Diffraction analysis. Further disclosed herein are crystalline Form D valbenazine ditosylate in the form of a dichloromethane solvate, and crystalline Form E valbenazine ditosylate in the form of a hydrate. Also disclosed are pharmaceutical compositions comprising these new crystalline forms, and methods of using those compositions for the treatment of various disease states and conditions, including hyperkinetic disorder, such as drug-induced tardive dyskinesia and Tourette's syndrome.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: June 23, 2020
    Assignee: Farmhispania S.A.
    Inventors: Rafel Prohens López, Raquel Cordobilla Cascales, Xavier Pujol Ollé, Óscar Martínez Pérez
  • Patent number: 10689370
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 23, 2020
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Chengzhi Zhang, Justin Chakma
  • Patent number: 10676427
    Abstract: The present invention relates compounds useful as reagents for the diazomethylation reaction, their preparation and the use thereof as reagents in a method for the diazomethylation reaction of aromatic substrates. It relates in particular to a compound of formula (I) wherein E is an electron withdrawing group.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 9, 2020
    Assignee: FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ICIQ)
    Inventors: Marcos García Suero, Zhaofeng Wang
  • Patent number: 10669237
    Abstract: Provided herein is a process for the preparation of 4-((6-bromopyridin-3-yl)oxy)benzonitrile.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: June 2, 2020
    Assignee: Dow AgroSciences LLC
    Inventors: Nicholas R. Babij, Qiang Yang, Kaitlyn Gray, Yan Hao
  • Patent number: 10662207
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: May 26, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • Patent number: 10662167
    Abstract: The invention relates to a method for producing 5-hydroxymethylfurfural (HMF) in a continuous process, which leads to the obtainment of an HMF fraction, a carbohydrate/acid fraction, a fructose fraction, and a levulinic-acid and formic-acid fraction and advantageously makes it possible, because of the purity of the obtained fractions, to return the fructose fraction obtained by means of the method directly to the production process and to use the other fractions in further-processing processes without the need for complex, additional purification steps.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: May 26, 2020
    Assignee: SUDZUCKER AG
    Inventors: Markwart Kunz, Alireza Haji Begli, Christine Kröner, Wolfgang Wach, Alain-Michel Graf, Wolfgang Kraus
  • Patent number: 10654829
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 19, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • Patent number: 10654804
    Abstract: Disclosed are compounds of Formula 1, N-oxides of the compounds and salts of the compounds and N-oxides: wherein R1, R2, R3, R4, R5, R6, Q1, Q2, J, Y1, and Y2 are as defined in the disclosure. Also disclosed are compositions containing the compounds, N-oxides and salts, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of such a compound, N-oxide, salt or composition.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: May 19, 2020
    Assignee: FMC Corporation
    Inventors: Andrew Duncan Satterfield, Matthew James Campbell, James Francis Bereznak, William Guy Whittingham, Glynn Mitchell, Christopher John Mathews, James Nicholas Scutt, James Alan Morris, Jonathan Wesley Paul Dallimore, Katharine Mary Ingram, Timothy Robert Desson, Kenneth Ling
  • Patent number: 10654821
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: May 19, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Patent number: 10654815
    Abstract: The present invention relates to a urea compound and a preparation method and an application thereof. The structure of the present compound is represented by formula (I), the definition of each variable in the formula being as described in the description. The compound can block interaction between the PD-1/PD-L1 signalling pathways. The compound of the present invention can be used for treating or preventing diseases related to the signalling pathways, such as cancer, autoimmune disease, chronic infectious disease, and other diseases.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: May 19, 2020
    Assignee: SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.
    Inventors: Qianjiao Yang, Xianping Lu, Zhibin Li, Lijun Xin, Yonglian Song, Chao Fu
  • Patent number: 10647700
    Abstract: An inhibitor of a wild type and Y641F mutant of human histone methyltransferase EZH2 is provided herein. Particularly, the inhibitor is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The inhibitor can be used to treat a cancer or precancerous condition related to EZH2 activity.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: May 12, 2020
    Assignee: TARAPEUTICS SCIENCE INC.
    Inventors: Qingsong Liu, Jing Liu, Fengchao Lv, Chen Hu, Wen Liang Wang, Ao Li Wang, Zi Ping Qi, Xiao Fei Liang, Wen Chao Wang, Tao Ren, Bei Lei Wang, Li Wang
  • Patent number: 10647712
    Abstract: A compound of general formula I: is disclosed. The compound be used to prevent or treat hepatitis B virus infection.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: May 12, 2020
    Assignee: SUZHOU ARK BIOPHARMACEUTICAL CO., LTD.
    Inventors: Cheng Peng, Qing Xu, Teng Feng, Xiashi Lv, Xiaogang Lai, Rui Cui, Shaoyun Zhang, Jian Han, Chaojun Gong, Zhaoxiong Cai, Yang Zhou, Gang Zou, Danbin Li, Haiqing Yuan, Zhen Jim Wu
  • Patent number: 10639279
    Abstract: The compound according to the present embodiment is represented by the following formula (1): Q-L-CHR2??(1) (wherein, Q is a non-cationic aliphatic group that does not contain nitrogen but contains oxy; L is a single bond or an aliphatic group containing no nitrogen; Rs are C12-C24 aliphatic group, the same or different; and at least one R contains, in the main chain or side chain thereof, a linking group LR selected from the group consisting of —C(?O)—O—, —O—C(?O)—, —O—C(?O)—O—, —S—C(?O)—, —C(?O)—S—, —C(?O)—NH—, and —NH—C(?O)—).
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 5, 2020
    Assignee: KABUSHIKI KAISHA TOSHIBA
    Inventors: Mitsuko Ishihara, Eiichi Akahoshi, Katsuyuki Naito
  • Patent number: 10644242
    Abstract: Oligomeric compounds useful as organic conjugated materials in electronic devices. Oligomeric compounds contain three or more or four or more of certain PDI units bonded to an organic core. The organic core contains one, two or more thiophene rings. The organic core can contain two or more thiophene rings separated by a linker group; two or more thiophene rings directly fused to each other or indirectly fused to each other through an optionally substituted aromatic or non-aromatic carbocylic ring system or an optionally substituted aromatic heterocyclic or non-aromatic heterocyclic ring system; or each of two or more thiophene rings is fused to an aromatic or non-aromatic carbocylic ring system or an aromatic heterocyclic or non-aromatic heterocyclic ring system and the resulting fused rings containing a thiophene ring are each separated by a linker group M. Methods for making oligomeric compounds by direct heteroarylation are provided.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: May 5, 2020
    Assignee: UTI Limited Partnership
    Inventors: Abby-Jo Payne, Gregory C. Welch
  • Patent number: 10640483
    Abstract: The present invention provides salts of (E)-N,N-dimethyl-4-((2-((5-((Z)-4,4,4-trifluoro-1-(3-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)pyridin-2-yl)oxy)ethyl)amino)but-2-enamide represented by the formula I and acids, and crystals thereof, possessing a potential to be used as drug substance in pharmaceuticals.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: May 5, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventor: Keiko Onuma
  • Patent number: 10640495
    Abstract: The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a single bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, and the group represented by is a group represented by Formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: May 5, 2020
    Assignee: Shionogi & Co., Ltd.
    Inventors: Akira Yukimasa, Kenichiroh Nakamura, Masanao Inagaki, Kazuya Kano, Motohiro Fujiu, Hiroki Yamaguchi, Kayoko Hata, Takatsugu Inoue
  • Patent number: 10640518
    Abstract: To provide novel pesticides, especially insecticides or acaricides. A condensed heterocyclic compound represented by the formula (1) or its salt, or N-oxide thereof: wherein Q is a structure represented by Q1, Q2 or the like, D substituted with —S(O)nR1 is a structure represented by D1 or D2, A1 is N(A1a) or the like, A1a is C1-C6 alkyl or the like, A4 is a nitrogen atom or C(R4), A5 is a nitrogen atom or C(R5), R1 is C1-C6 alkyl or the like, each of R2, R5 and R6 is independently a hydrogen atom or C1-C6 alkyl, each of R3, R4, Y1, Y2, Y3 and Y4 is independently a halogen atom, halo (C1-C6) alkyl or the like, and n is an integer of 0, 1 or 2.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: May 5, 2020
    Assignee: Nissan Chemical Corporation
    Inventors: Takao Kudo, Keisuke Tsuji, Kenkichi Noto, Yukihiro Maizuru, Hiroto Matsui, Masaki Kobayashi, Hotaka Imanaka
  • Patent number: 10633392
    Abstract: The present invention provides unified synthesis of the CI-CI 9 building blocks of halichondrins and analogs thereof using selective coupling of poly-halogenated nucleophiles in chromium-mediated coupling reactions. The present invention also provides a practical and efficient synthesis of C20-C38 building blocks of halichondrins and analogs thereof. Also provided herein are general methods of selective activation and coupling of poly-halogenated analogs with an aldehyde. The provided coupling reactions are selective for halo-enone and halo-acetylenic ketal over vinyl halide and halide attached to a sp hydridized carbon. The provided efficient selective coupling reactions can allow easy access to the CI-CI 9 building blocks and C20-C38 building blocks of halichondrins and analogs thereof with limited or no purification or separation of the intermediates.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 28, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Yoshito Kishi, Wuming Yan, Jingwei Li, Zhanjie Li, Kenzo Yahata